Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe.
Future Oncol
; 19(31): 2103-2121, 2023 Oct.
Article
en En
| MEDLINE
| ID: mdl-37706245
There are many new treatments available for patients with multiple myeloma. While outcomes such as survival, symptoms and health problems experienced have improved, patients still continue to relapse and fall ill again. This means their current treatment stops working and they have to change to a new treatment to prevent their disease from developing further. Patients who have received three different types of treatment are classed as being 'tri-exposed', and they experience greater problems with their health. To better understand this course of events, we used information from a survey of doctors and their patients with multiple myeloma across Europe in 2021. We looked at patient's symptoms, the treatments they received, how and when they accessed healthcare (including hospital visits and tests) and the overall difficulties experienced due to their illness. We found that patients were broadly treated according to the most recent European guidelines, although differences were seen between countries. When patients had to switch therapy, the type of treatment received next depended on what they had previously been prescribed, meaning that treatment choices became increasingly complicated. Overall, 25% of patients in our study were classed as tri-exposed, and had more hospitalisations, required more hospital tests, had greater health problems and experienced more difficulties at work than those who were not tri-exposed. Despite recent developments in the treatment of multiple myeloma, there is still a need for more effective therapies. This is especially true for patients who are tri-exposed, who have limited treatment options and experienced greater health problems.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Mieloma Múltiple
Tipo de estudio:
Guideline
/
Qualitative_research
Aspecto:
Patient_preference
Límite:
Humans
País/Región como asunto:
Europa
Idioma:
En
Revista:
Future Oncol
Año:
2023
Tipo del documento:
Article
País de afiliación:
España
Pais de publicación:
Reino Unido